Vrishank Raghav

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Valve-in-valve transcatheter aortic valve replacement (VIV-TAVR) has proven to be a successful treatment for high risk patients with failing aortic surgical bioprostheses. However, thrombus formation on the leaflets of the valve has emerged as a major issue in such procedures, posing a risk of restenosis, thromboembolism, and reduced durability. In this(More)
  • 1